Results A total of 775 adults with an increased risk of serious disease progressed in the study. The pharmaceutical company states that they have compared the number of admissions and deaths within 30 days among those who received the tablet with a control group who received deceptive medicine.

– The study showed that 14.1 percent of those who received deceptive medication were admitted, while 7.3 percent of those who received medication were admitted. The reduction in admissions is a useful clinical effect. Such a drug can be important in a situation where many people are infected, and can help relieve the hospitals, says Madsen. – There are also a number of details we need to know more about. For example, it must be investigated whether the patients who receive treatment will also have increased immunity to covid-19, or whether they will be more exposed to infection after treatment. Much of this will not be known for sure until the drug has been in use for a while.

– Useful for all countries Madsen adds that will be exciting to look at the data basis.

– And then it will be exciting to look more closely at the data from the clinical studies, because the pharmaceutical companies tend to exaggerate their own results, so it is of course very important to study the complete data base. – What significance can this have for Norway?

– It will be useful for all countries to get a drug that reduces the risk of serious illness in people who have been diagnosed with covid-19. It is envisaged that this type of medicine may be useful to have in hand in many countries, but it is as we always say: Only vaccination can take us out of this pandemic.

Note: This article has been indexed to our site. We do not claim ownership or copyright of any of the content above. To see the article at original source Click Here